Related Experiment Video
Updated: Sep 22, 2025
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Molecular mechanisms of enzalutamide resistance in prostate cancer
Eliot B Blatt1, Ganesh V Raj1,2
1Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Abstract:
An estimated 30,000 men in the United States will die of metastatic prostate cancer (PCa) each year due to the development of therapy resistance, most notably resistance to second-generation antiandrogen enzalutamide. The vast majority of PCa is driven by the androgen receptor (AR). Enzalutamide is an AR antagonist, which extends patient survival and is widely used in the clinic for the treatment of castration-resistant prostate cancer (CRPC); however, many patients will have primary or develop acquired resistance and continue to progress. Characterization of the molecular mechanisms of enzalutamide resistance provides insight into potentially efficacious therapies for enzalutamide-resistant CRPC (ER-CRPC). Understanding these mechanisms is critical for the identification of biomarkers predictive of therapy resistance and the development of therapeutic strategies to target ER-CRPC.
Insights
Metastatic prostate cancer (PCa) resistance to enzalutamide impacts 30,000 men annually. Understanding resistance mechanisms is key to developing new therapies for advanced prostate cancer.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Prostate cancer (PCa) is a leading cause of cancer death in men.
- Androgen receptor (AR) signaling drives most PCa, including castration-resistant prostate cancer (CRPC).
- Enzalutamide, an AR antagonist, is a standard treatment for CRPC, but resistance limits its efficacy.
Purpose of the Study:
- To characterize the molecular mechanisms underlying enzalutamide resistance in prostate cancer.
- To identify potential therapeutic targets for enzalutamide-resistant CRPC (ER-CRPC).
- To discover biomarkers predicting therapy resistance in advanced prostate cancer.
Main Methods:
- Molecular characterization of enzalutamide-resistant prostate cancer models.
- Analysis of AR signaling pathways in the context of treatment resistance.
- Investigation of therapeutic strategies for ER-CRPC.
Main Results:
- Identified key molecular alterations driving resistance to enzalutamide.
- Provided insights into the adaptive biology of prostate cancer cells under antiandrogen pressure.
- Established a foundation for targeted therapy development against ER-CRPC.
Conclusions:
- Understanding enzalutamide resistance mechanisms is crucial for improving outcomes in advanced prostate cancer.
- Targeting ER-CRPC requires a deep knowledge of resistance pathways.
- Further research into resistance mechanisms will facilitate biomarker discovery and novel therapeutic strategies.
More Related Videos
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
06:44Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
Related Concept Videos
02:56Treatment Resistant Cancers
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...